

Product Pipeline

	Code No. (Generic Name)	Stage						
		Ph I	Ph IIa	Ph IIb	Ph III	NDA Submitted	Launched	
Three Targeted R&D Areas	Infection Disease	S-4661 (Doripenem hydrate)	Sept. 2005					
			USA Complicated intra-abdominal infections, Complicated urinary tract infections, including pyelonephritis Oct. 2007					
			USA Hospital-acquired (nosocomial) pneumonia, including ventilator-associated pneumonia June 2007					
			EU July 2008					
			BAY12-8039 (Moxifloxacin hydrochloride) Dec. 2005					
	S-021812 (Peramivir)	Asian multi-national study (Phase III)			NDA filing in preparation			
	S-013420 (Modithromycin)							
	S-349572/S-265744/S-247303	USA						
		EU						
	Pain	S-81116 (Oxycodone hydrochloride)	Feb. 2007					
LY248686 (Duloxetine hydrochloride)		NDA filing in preparation						
S-811717 (Oxycodone hydrochloride)								
S-297995								
Metabolic Syndrome	S-4522 (Rosuvastatin)	Apr. 2005						
	SR47436 (Irbesartan)	July 2008						
	S-2367 (Velneperit)	USA						
		Japan						
S-3013 (Varespladib methyl)	USA							
	EU							
Allergies	SCH29851 (Loratadine)	Jan. 2008						
	S-555739	Japan						
		EU						
S-444823								
Frontier Areas	Others	NS75A (Cetorelix acetate)	Sept. 2006					
		CD-271 (Adapalene gel)	Oct. 2008					
		S-7701 (Pirfenidone)	Dec. 2008					
	LY248686 (Duloxetine hydrochloride)	Jan. 2008						
	NS75B (Cetorelix pamoate)							
	S-0139	Japan						
		EU						
	S-0373							
	S-888711	Japan						
USA								
S-222611	EU							

- In-house product
- ▲ Out-licensed product
- In-licensed product

(as of August 2009)

Category (Administration)	Indication	Origin [Licensee]	Development Area	Product Name
Carbapenem antibiotic (Injection)	Bacterial infection	● In-house	Japan	Finibax®
	Pediatric infection	● In-house	Japan	
	Addition of new dosage regimen (1g t.i.d. for serious infection)	● In-house	Japan	
	Bacterial infection	▲ In-house [Johnson & Johnson]	USA Europe	
New quinolone antibiotic (Oral)	Bacterial infection	■ Bayer Yakuin (Japan)	Japan	Avelox®
Neuraminidase inhibitor (Injection)	Influenza infection	■ BioCryst Pharmaceuticals, Inc. (USA)	Asia	
Novel macrolide antibiotic (Oral)	Bacterial infection	■ Enanta Pharmaceuticals, Inc. (USA)	Japan	
Integrase inhibitor (Oral)	HIV infection	● Shionogi-GlaxoSmithKline	In-house product being developed globally	
Immediate-release oxycodone (Oral)	Cancer pain	■ Mundipharma AG (Netherlands)	Japan	OxiNorm™
SNRI (serotonin & noradrenaline reuptake inhibitor) (Oral)	Diabetic peripheral neuropathic pain	■ Eli Lilly and Company (USA)	Japan	
Natural opium alkaloids (Injection)	For the treatment of moderate to severe pain in patients with cancer pain	■ Napp Pharmaceutical Limited (UK)	Japan	
Peripheral opioid receptor antagonist (Oral)	Alleviation of opioid-induced adverse effect	● In-house	In-house product being developed globally	
HMG CoA reductase inhibitor (Oral)	Hyperlipidemia	▲ In-house [AstraZeneca]	Japan	Crestor®
Angiotensin II receptor antagonist (Oral)	Hypertension	■ Sanofi SA (France)	Japan	Irbetan®
Neuropeptide Y Y5 receptor antagonist (Oral)	Obesity	● In-house	In-house product being developed globally	
Secretory PLA2 (sPLA2) inhibitor (Oral)	Acute coronary syndromes Mixed dyslipidemia	▲ Shionogi & Eli Lilly and Company (USA) [Anthera Pharmaceutical, Inc.]	USA/Europe	
Histamine H1 receptor antagonist (Oral)	Allergic rhinitis and itch caused by various dermatitis	■ Schering-Plough Corp. (USA)	Japan	Claritin® Dry Syrup
Prostaglandin D2 receptor antagonist (Oral)	Allergic disease	● In-house	In-house product being developed globally	
Cannabinoid receptor agonist (Topical)	Atopic dermatitis	● In-house	In-house product being developed globally	
Gonadotropin releasing hormone antagonist (SC)	Premature ovulation inhibitor	■ Zentaris AG (Germany)	Japan	Cetrotide®
Retinoic acid nuclear receptor agonist (Topical)	Acne vulgaris	■ Galderma (France)	Japan	Differin® Gel
Anti-fibrosis (Oral)	Idiopathic interstitial pulmonary fibrosis	■ Marnac, Inc. (USA) ■ KDL (Japan)	Japan	Pirespa®
SNRI (serotonin & noradrenaline reuptake inhibitor) (Oral)	Depression	■ Eli Lilly and Company (USA)	Japan	
Gonadotropin releasing hormone antagonist (Injection)	Benign prostatic hypertrophy	■ Aeterna Zentaris GmbH (Canada)	Japan	
Endothelin A receptor antagonist (Injection)	Cerebrovascular diseases	● In-house	Japan/Europe	
Non-peptide mimetic of TRH (Oral)	Spinocerebellar ataxia	▲ In-house [Kissei Pharmaceutical Co., Ltd.]	Japan	
Small molecule TPO mimetic (Oral)	Thrombocytopenia	● In-house	In-house product being developed globally	
Her2/EGFR dual inhibitor (Oral)	Malignant tumors	● In-house	In-house product being developed globally	